Early access
Sign in
Taking people in United StatesNo phase

Voice recordings to watch for nerve-related side effects of CAR T-cell therapy

Looks at voice recordings to monitor side effects in adults receiving CAR T-cell therapy.

Key facts

Who runs it
Memorial Sloan Kettering Cancer Center
Where
Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, and Rockville Centre, United StatesSee the 8 sites
Trial code
Registry title
A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
Status
Recruiting
People taking part
20 people, planned
Started
17 Apr 2026
Expected to end
Dec 2027
Type of study
Observational
Treatments tested
  • Audio Tasks
Record updated
13 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with non-Hodgkin lymphoma or multiple myeloma who are about to get an approved CAR T-cell therapy. They will record their voice and have daily nerve checks.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Non-Hodgkin lymphoma or multiple myeloma, confirmed by pathology. ECOG performance status of 2 or lower.
Earlier treatment
Must be scheduled to receive an FDA-approved CAR-T product: Axi-cel, Liso-cel, Tisa-cel, Ide-cel, Cilta-cel, or Brexu-cel.

Main reasons for not taking part

  • Nerve conditions that clearly harm speech, such as severe dysarthria, expressive aphasia or neurodegenerative disorders
  • Voice or vocal cord problems, such as laryngeal paralysis, severe dysphonia, nodules, polyps or recent vocal cord surgery or radiation
  • Severe hearing impairment that would get in the way of voice assessments
  • No smartphone, or not enough spoken English to do the voice tasks
  • Cannot do twice daily voice recordings or daily neurologic assessments

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Documentation of Disease; o Patients must have pathologically confirmed Diagnosed with non-Hodgkin lymphoma or multiple myeloma
  • Definition of treatment and ability; Scheduled to receive an FDA-approved CAR-T product: Axi-cel, Liso-cel, Tisa-cel, Ide-cel, Cilta-cel, or Brexu-cel; Ability to comply with twice daily voice recordings or daily neurologic assessments, as determined by the investigator
  • Age ≥ 18
  • ECOG Performance Status of ≤ 2
  • Required; Perform twice daily voice recordings using a smartphone; Undergo daily neurologic assessments (e.g., ICE score, tremor evaluation); Smartphone ownership; Sufficient English proficiency to complete structured voice tasks in the study application
  • Comorbid Conditions; No pre-existing neurological conditions that significantly impair speech, including but not limited to severe dysarthria, expressive aphasia, or neurodegenerative disorders; No history of significant speech or voice disorders, including laryngeal paralysis, severe dysphonia, or recent vocal cord surgery or radiation to the area; No pathology affecting the vocal cords that could interfere with voice analysis, such as vocal cord paralysis, chronic laryngitis, vocal cord nodules, polyps, granulomas, or malignancies; No severe hearing impairment that would interfere with voice assessments
  • Language o Proficiency in spoken English is required, without the need for native-level fluency. This ensures participants can accurately perform structured voice tasks, as the application and underlying acoustic models are currently validated only in English, despite the limitation in generalizability. Participants with language barriers that prevent reliabletask completion or data interpretation will be excluded

Where in United States

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)Basking Ridge, United StatesContact: Roni Shoulval, MD, PhDTaking people
  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)Commack, United StatesContact: Roni Shouval, MD, PhDTaking people
  • Memorial Sloan Kettering Westchester (Consent only)Harrison, United StatesContact: Roni Shouval, MD, PhDTaking people
  • Memorial Sloan Kettering Monmouth (Consent Only)Middletown, United StatesContact: Roni Shouval, MD, PhDTaking people
  • Memorial Sloan Kettering Bergen (Consent Only)Montvale, United StatesContact: Roni Shouval, MD, PhDTaking people
  • Memorial Sloan Kettering Cancer Center (All Protocol Activites)New York, United StatesContact: Roni Shouval, MD, PhDTaking people
  • Weill Cornell Medical Center (Data Analysis Only)New York, United StatesContact: Alexandros SigarasNot yet recruiting
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)Rockville Centre, United StatesContact: Roni Shouval, MD, PhDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to collect voice recordings and nervous system (neurologic) assessments from people with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) who are receiving standard treatment with CAR T-cell therapy. Researchers will study whether these voice recordings and assessments are a practical (feasible) way to monitor for immune effector cell-associated neurotoxicity syndrome (ICANS). Feasibility will be measured by tracking how many participants join the study and complete the assessments.

The group in the trial

  • Participants diagnosed with non-Hodgkin lymphoma or multiple myeloma

    Participants must have pathologically confirmed Diagnosed with non-Hodgkin lymphoma or multiple myeloma.

    Treatment: Audio Tasks

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Voice as a Digital Biomarker of Neurotoxicity in CAR T-Cell Therapy
Plain-language title
Voice recordings to watch for nerve-related side effects of CAR T-cell therapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
13 October 2026